PRESS RELEASE published on 06/25/2025 at 18:00, 7 months 9 days ago Oxurion Receives Transparency Notification from Atlas Special Opportunities II LLC Oxurion NV received a transparency notification from Atlas Special Opportunities II, LLC indicating a decrease in shareholding below the threshold. The biopharmaceutical company is focused on therapeutic innovation and clinical research technologies Technology Clinical Research Transparency Notification Biopharmaceutical Oxurion NV
BRIEF published on 06/19/2025 at 08:35, 7 months 16 days ago Oxurion to Acquire Preclinical Microbiology CRO in Toulouse Acquisition Diversification Toulouse Oxurion Microbiology CRO
BRIEF published on 06/19/2025 at 08:35, 7 months 16 days ago Oxurion acquiert une CRO en microbiologie préclinique à Toulouse Acquisition Diversification Toulouse Oxurion CRO En Microbiologie
PRESS RELEASE published on 06/19/2025 at 08:30, 7 months 16 days ago Oxurion ondertekent intentieverklaring voor de voorgenomen overname van een preklinische microbiologie-CRO om zich te diversifiëren en zijn aanwezigheid in de regio Toulouse te versterken Oxurion NV, een biofarmaceutisch bedrijf in Leuven, kondigt intentieovereenkomst voor de overname van onderneming gespecialiseerd in microbiologische diensten aan, ter versterking van expertise en strategie Stratégie Overname Oxurion NV Biofarmaceutisch Microbiologische Diensten
PRESS RELEASE published on 06/19/2025 at 08:30, 7 months 16 days ago Oxurion signs a letter of intent for the planned acquisition of a preclinical microbiology CRO to diversify and strengthen its presence in the Toulouse region Oxurion NV announces LOI to acquire 70% share capital of preclinical microbiology services company. Economic details of the transaction and growth projections disclosed Acquisition Transaction Details Growth Projections Oxurion NV Preclinical Microbiology
PRESS RELEASE published on 06/19/2025 at 08:30, 7 months 16 days ago Oxurion signe une lettre d'intention pour l'acquisition projetée d'une CRO de services précliniques en microbiologie afin de se diversifier et de renforcer sa présence en région toulousaine Oxurion NV signe une lettre d'intention pour l'acquisition de 70% d'une société spécialisée en microbiologie appliquée à la santé humaine et animale, dermocosmétiques et nutraceutiques Acquisition Biopharmaceutique Lettre D'intention Oxurion NV Microbiologie Appliquée
BRIEF published on 06/18/2025 at 18:05, 7 months 16 days ago Oxurion Announces Transparency Notification from Atlas Special Opportunities II LLC Transparency Notification Biopharmaceutical Atlas Special Opportunities Ownership Structure Oxurion
BRIEF published on 06/18/2025 at 18:05, 7 months 16 days ago Oxurion annonce une notification de transparence de la part d'Atlas Special Opportunities II LLC Biopharmaceutique Notification De Transparence Oxurion Opportunités Spéciales Atlas Structure De Propriété
PRESS RELEASE published on 06/18/2025 at 18:00, 7 months 16 days ago Oxurion Receives Transparency Notification from Atlas Special Opportunities II LLC Oxurion NV announces receipt of transparency notification from Atlas Special Opportunities II, LLC regarding shareholding. Company combines therapeutic innovation with technology for clinical research Clinical Research Transparency Notification Biopharmaceutical Belgium Oxurion NV
PRESS RELEASE published on 06/18/2025 at 18:00, 7 months 16 days ago Oxurion ontvangt transparantiekennisgeving van Atlas Special Opportunities II LLC Oxurion NV ontvangt transparantiekennisgeving van Atlas Special Opportunities II LLC, verlaagt aandeel tot onder drempel 20%. Biofarmaceutisch bedrijf in Leuven kondigt belangrijke ontwikkeling aan Transparantiekennisgeving Oxurion NV Biofarmaceutisch België Atlas Special Opportunities II LLC
Published on 02/05/2026 at 09:05, 2 hours 24 minutes ago BioNxt Secures Innovative Chaperone Technology to Enhance Oral Thin-Film Drug Delivery
Published on 02/05/2026 at 01:35, 9 hours 54 minutes ago Dr. Ruben Shiffman Files Early Warning Report in Respect of Greenland Resources
Published on 02/05/2026 at 00:00, 11 hours 29 minutes ago Onco-Innovations Announces Filing of Preliminary Base Shelf Prospectus
Published on 02/04/2026 at 22:25, 13 hours 4 minutes ago 55 North Mining Announces Flow-Through Financing
Published on 02/05/2026 at 11:16, 13 minutes ago FUCHS strengthens its presence in Türkiye with the complete takeover of the joint venture OPET FUCHS
Published on 02/05/2026 at 10:48, 41 minutes ago EQS-Adhoc: Evonik Industries AG: Executive Board adjusts dividend policy
Published on 02/05/2026 at 10:05, 1 hour 24 minutes ago VT Markets Powers Reliable Gold Trading Amid Extreme Market Volatility
Published on 02/05/2026 at 10:05, 1 hour 24 minutes ago Signing of strategic technology supply and offtake agreement with Carester, US$20 million equity investment from the Industrial Development Corporation, and commencement of DFS for the Zandkopsdrift magnet rare earths and battery grade manganese
Published on 02/04/2026 at 18:04, 17 hours 25 minutes ago Capital et droits de vote au 31 janvier 2026
Published on 02/04/2026 at 18:04, 17 hours 25 minutes ago Total number of voting rights and shares making up the share capital at January 31, 2026
Published on 02/04/2026 at 17:45, 17 hours 44 minutes ago Information concerning the total number of voting rights and shares 2026 01 31
Published on 02/04/2026 at 17:45, 17 hours 44 minutes ago MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL